InTouch and ASCO Announce New Cancer Information Feature

Publication
Article
OncologyONCOLOGY Vol 16 No 4
Volume 16
Issue 4

InTouch magazine, the Good Health Guide to Cancer Prevention and Treatment, has joined forces with the American Society of Clinical Oncology (ASCO).

InTouch magazine, the Good Health Guide toCancer Prevention and Treatment, has joined forces with the American Society ofClinical Oncology (ASCO). Beginning with the May 2002 issue of InTouch, ASCOwill contribute a regular page to the magazine, which is published six times ayear.

"InTouch is committed to providing cancer patients andtheir families with comprehensive information on cancer prevention and treatmentoptions," said Randi Londer Gould, managing editor of InTouch."Teaming with ASCO adds strength to our efforts and broadens the scope ofthe resources we provide for our readers."

The new feature combines the oncologist-approved cancerinformation contained in InTouch with the latest news from ASCO. The debutcolumn will highlight ASCO’s patient information materials and onlineresources, including their new cancer information website, People Living WithCancer, scheduled to launch in May.

"ASCO is all about taking care of patients," saidLarry Norton, MD, ASCO President. "ASCO serves the people who treat peoplewith cancer. This collaboration with InTouch, which shares our commitment toenhancing patient-physician communication, will enable ASCO to reach even morepatients with the information they need to make informed decisions about theirhealth care."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.